Non-myeloablative allogenic peripheral blood stem cell transplantation in a patient with refractory osteosarcoma.
The prognosis of patients with relapsed osteosarcoma is dismal despite the use of intensive chemotherapy. We describe a patient with refractory osteosarcoma who underwent non-myeloablative peripheral blood stem cell transplantation (PBSCT) from an human leukocyte antigen (HLA)-identical sibling during a third complete remission. The patient suffered pulmonary relapse after the transplantation. Cyclosporin A withdrawal induced a graft-vs.-osteosarcoma effect and graft-vs.-host disease, but eventually the tumor progressed. Although our experience in this case suggested the presence of a graft-vs.-osteosarcoma effect during non-myeloablative allogenic PBSCT, this strategy might have limited value for refractory osteosarcoma with rapid growth kinetics.
Kounami
Shinji
S
Department of Pediatrics, Wakayama Medical University, Wakayama City, Japan. nami@mail.wakayama-med.ac.jp
Nakayama
Keiko
K
Yoshiyama
Megumi
M
Yoshimasu
Tetsu
T
Aoyagi
Noriyuki
N
Yoshikawa
Norishige
N
D000293:Adolescent; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D002908:Chronic Disease; D018450:Disease Progression; D017809:Fatal Outcome; D006086:Graft vs Host Disease; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D017211:Treatment Failure